DDIT3 and lymphoma: Twenty-seven iPET-negative patients with CD20-negative lymphoma received six cycles of CHOP, 224 and 174 iPET-negative patients with CD20-positive lymphoma received six cycles of R-CHOP or six cycles of R-CHOP followed by two doses of rituximab, and 30 and 26 iPET-positive patients received eight cycles of (R-)CHOP or two cycles of (R-)CHOP followed by six cycles of the Burkitt protocol (rituximab restricted to CD20-positive lymphoma).